Skip to content

FemBloc® Permanent Contraception - Early Pivotal Trial

BLOC: Prospective Multi-Center Office Based Bi-Lateral Tubal Occlusion Trial for Female Permanent Contraception

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03433911
Acronym
BLOC
Enrollment
240
Registered
2018-02-15
Start date
2018-02-02
Completion date
2025-02-10
Last updated
2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contraception

Keywords

Permanent contraception, Birth control

Brief summary

Prospective, multi-center, international, non-randomized, two-arm study of subjects undergoing either FemBloc or laparoscopic bilateral tubal sterilization (Control). The FemBloc group total study duration will be approximately 65 months. The laparoscopic tubal sterilization (Control) group total study duration will be approximately 62 months.

Interventions

DEVICEFemBloc

Treatment with FemBloc for women who desire permanent birth control (female sterilization)

PROCEDURELaparoscopic bilateral tubal sterilization

Laparoscopic bilateral tubal sterilization for women who desire permanent birth control (female sterilization)

Sponsors

Femasys Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
21 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Female, 21 - 45 years of age desiring permanent birth control * Sexually active with male partner * For FemBloc Arm: * Regular menstrual cycle for last 3 months or on hormonal contraceptives * For Control Arm: * Undergoing planned laparoscopic bilateral tubal sterilization

Exclusion criteria

* Uncertainty about the desire to end fertility * Known or suspected pregnancy * Prior tubal surgery, including sterilization attempt * Prior endometrial ablation * Presence, suspicion, or previous history of gynecologic malignancy * Abnormal uterine bleeding requiring evaluation or treatment * Scheduled to undergo concomitant intrauterine procedures at the time of procedure(s)

Design outcomes

Primary

MeasureTime frameDescription
Incidence of short-term and long-term adverse events in each arm1-5 yearsSafety: Incidence of short-term and long-term adverse events in each arm

Countries

United States

Contacts

STUDY_DIRECTORSponsor

Medical Affairs & Clinical Development

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026